Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-(5-chloro-2,4-dihydroxyphenyl)-N‑ethyl‑4‑(4‑methoxyphenyl)‑1H‑pyrazole‑3-carboxamide is a synthetic small molecule that acts as an inhibitor of heat shock protein 90 (Hsp90). It belongs to the class of phenylpyrazoles and resorcinol derivatives. Hsp90 is a molecular chaperone involved in the folding and stabilization of many client proteins, including several oncogenic kinases. Inhibition of Hsp90 can disrupt multiple signaling pathways critical for cancer cell survival and proliferation. This compound has been studied primarily as a chemical probe or experimental agent in preclinical research settings[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)-1H-pyrazole-3-carboxamide.